ClinicalTrials.gg
TerminatedNCT00503698OPPORTUNITYUpdated Mar 7, 2017Results posted

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

A Phase 3 interventional study of somatropin and placebo in Chronic Kidney Disease and End-Stage Renal Disease, sponsored by Novo Nordisk A/S. Terminated at 381 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-07.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
See termination reason in detailed description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
712
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 96 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
48th of 638
712 · median 48
Started
2007
with 35 others
Phase 3
76 of 765
4 open now
Registered
106th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 48th largest by enrollment of the 638 interventional ones that give a count, is one of 36 that started in 2007, is one of 76 in phase 3, and was the 106th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Asia, Europe, North and South America and Oceania.

The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.

Read the detailed description

The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.

03

Conditions studied

  • Chronic Kidney Disease
  • End-Stage Renal Disease

Browse trials for

04

In context

Kidney Failure, Chronic Reclassified

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's enrollment of 712 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum albumin as specified in protocol
  • Malnourished (based on serum albumin value below 40 g/L, assessed centrally)
  • Stable (for 3 months or more) and adequate haemodialysis treatment three months prior to enrolment as defined by Kt/V of more than 1.2

Exclusion criteria

Exclusion Criteria:

  • Active malignant disease
  • Critical illness requiring treatment in an intensive care unit (ICU)
  • Uncontrolled treated/untreated hypertension
  • Patients on chronic (more than 3 months) treatment with in doses of more than 10 mg/day prednisolone (or equivalent)
  • Patients treated with agents
  • Known Growth Hormone Deficiency
  • Patients suffering from any disease history in the opinion of the investigator
  • Severe illness as defined in the protocol (as judged by the investigator)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
712 participants (actual)

Study arms

  • Experimental
    Somatropin

    Somatropin once daily from week 0 to end of trial

    Drug: somatropin

  • Placebo comparator
    Placebo

    Placebo once daily to end of trial

    Drug: placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Mortality - Time to All-cause Death

    Time to all-cause death. Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants dead estimated using Kaplan-Meier. Summary data illustrates mortality until 52 weeks, because very few subjects had trial time longer than 52 weeks. Due to early trial termination, median trial time was 17.4 weeks.

    Time frame: week 0, trial termination

Secondary outcomes

  1. Morbidity - Time From Randomisation to Next Cardiovascular Event (Defined as Composite of All-cause Mortality, Non-fatal Myocardial Infarction, Stroke, Cardiac Insufficiency and Other Thrombo-embolic Event)

    Morbidity - time from week 0 to next cardiovascular event (composite of all-cause mortality and cardiovascular events defined as adjudicated medical event of special interest and categorised as myocardial infarctions, cardiac insufficiencies, strokes or other thrombo-embolic events). Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants with events estimated using Kaplan-Meier. Summary data illustrates morbidity until 52 weeks, because very few subjects had trial time longer than 52 weeks.

    Time frame: week 0, trial termination

  2. Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures

    The number of times that the patient was hospitalised in addition to hospitalisation for normal dialysis procedures measured from week 0 (randomisation) to the time the trial was terminated.

    Time frame: week 0, trial termination

  3. Mortality - Two-year Mortality Rate

    Time frame: week 0, trial termination

  4. Health Related Quality of Life Assessments

    Summary from activity of daily living from the Rotterdam Symptom Checklist (RSCL) measuring activity from 1 (active) to 5 (inactive). The Edmonton Symptom Assessment System (ESAS), subjects assess their health in the last 24 hours on a scale from 1 (good health) to 3 (feeling poorly). The EQ-5D is a measure of subjects' health outcome from 0 (death) to 1 (full health). SF-36 (Short Form (36)) covering mental and physicial health is provided in a scale from 0-100 with higher scores indicating greater satisfaction.

    Time frame: week 0, trial termination

08

Results

Posted Jul 13, 2010
Limitations and caveats
Trial terminated early due to slow recruitment, which largely reduced the power of showing differences. The end of trial visit was used to describe week 104.

Participant flow

A total of 202 sites in 17 countries: United States, Canada, United Kingdom, Sweden, Denmark, France, Germany, Poland, Hungary, Spain, Portugal, Turkey, Israel, Argentina, Brazil, Russia, South Africa. Italy planned to participate but never randomised any subjects.

Participant flow — Overall Study
MilestoneSomatropinPlacebo
Started357355
Exposed to trial drug346349
Completed00
Not completed357355
Withdrew: Protocol violation56
Withdrew: Adverse event5241
Withdrew: Death10
Withdrew: Lack of efficacy34
Withdrew: Trial terminated216253
Withdrew: End hemodialysis due to renal transplant104
Withdrew: Pregnancy/intention to become pregnant10
Withdrew: Any condition in exclusion criteria46
Withdrew: Switch to peritoneal or home dialysis22
Withdrew: Move to nonparticipating dialysis center21
Withdrew: Critically ill20
Withdrew: Unclassified4832
Withdrew: Not exposed to trial drug116

Outcome measures

PrimaryMortality - Time to All-cause Death

Time to all-cause death. Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants dead estimated using Kaplan-Meier. Summary data illustrates mortality until 52 weeks, because very few subjects had trial time longer than 52 weeks. Due to early trial termination, median trial time was 17.4 weeks.

Time frame:
week 0, trial termination
Reported as:
Number · percentage of participants
Mortality - Time to All-cause Death
percentage of participantsSomatropinPlacebo
Baseline (week 0)0 ± NA0 ± NA
Week 2688
Week 441317
Week 522923
Statistical analysis
  • Somatropin vs Placebo · Regression, Cox · p = 0.91 · Cox proportional hazard: 0.97 · 95% CI 0.60 to 1.57Time to all-cause death analysed using stratified Cox regression model with treatment and sex as fixed factors, age and time in dialysis as covariates
SecondaryMorbidity - Time From Randomisation to Next Cardiovascular Event (Defined as Composite of All-cause Mortality, Non-fatal Myocardial Infarction, Stroke, Cardiac Insufficiency and Other Thrombo-embolic Event)

Morbidity - time from week 0 to next cardiovascular event (composite of all-cause mortality and cardiovascular events defined as adjudicated medical event of special interest and categorised as myocardial infarctions, cardiac insufficiencies, strokes or other thrombo-embolic events). Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants with events estimated using Kaplan-Meier. Summary data illustrates morbidity until 52 weeks, because very few subjects had trial time longer than 52 weeks.

Time frame:
week 0, trial termination
Reported as:
Number · percentage of participants
Morbidity - Time From Randomisation to Next Cardiovascular Event (Defined as Composite of All-cause Mortality, Non-fatal Myocardial Infarction, Stroke, Cardiac Insufficiency and Other Thrombo-embolic Event)
percentage of participantsSomatropinPlacebo
Baseline (week 0)0 ± 00 ± 0
Week 261217
Week 401823
Week 523124
Statistical analysis
  • Somatropin vs Placebo · Regression, Cox · p = 0.4977 · Cox proportional hazard: 0.88 · 95% CI 0.60 to 1.28Time to all-cause death analysed using stratified Cox regression model with treatment and sex as fixed factors, age and time in dialysis as covariates
SecondaryMorbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures

The number of times that the patient was hospitalised in addition to hospitalisation for normal dialysis procedures measured from week 0 (randomisation) to the time the trial was terminated.

Time frame:
week 0, trial termination
Reported as:
Mean · hospitalisations
Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures
hospitalisationsSomatropinPlacebo
Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures0.5 ± 0.90.5 ± 1.0
Statistical analysis
  • Somatropin vs Placebo · Negative binomial regression · p = 0.4409 · Rate ratio: 1.13 · 95% CI 0.83 to 1.53
SecondaryMortality - Two-year Mortality Rate
Time frame:
week 0, trial termination

No measurements were reported for this outcome.

SecondaryHealth Related Quality of Life Assessments

Summary from activity of daily living from the Rotterdam Symptom Checklist (RSCL) measuring activity from 1 (active) to 5 (inactive). The Edmonton Symptom Assessment System (ESAS), subjects assess their health in the last 24 hours on a scale from 1 (good health) to 3 (feeling poorly). The EQ-5D is a measure of subjects' health outcome from 0 (death) to 1 (full health). SF-36 (Short Form (36)) covering mental and physicial health is provided in a scale from 0-100 with higher scores indicating greater satisfaction.

Time frame:
week 0, trial termination
Reported as:
Mean · scores on a scale
Health Related Quality of Life Assessments
scores on a scaleSomatropinPlacebo
RSCL (overall mean), N= 316, 3122.9 ± 0.93.0 ± 0.9
ESAS (overall mean), N= 309, 3133.0 ± 1.93.0 ± 2.0
EQ-5D (UK overall score), N= 305, 2990.596 ± 0.3100.597 ± 0.321
SF-36 (overall physical health), N= 318, 31548 ± 2249 ± 22
SF-36 (overall mental health), N= 318, 31561 ± 2162 ± 21

Adverse events

Collected over The adverse events were collected from July 2007 to January 2009.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Somatropin—122/346 (35.3%)225/346 (65%)
Placebo—136/349 (39%)264/349 (75.6%)
Most frequent serious events
Showing 10 of 268
Most frequent serious events
EventSomatropinPlacebo
Cardiac failure congestiveCardiac disorders7/34612/349
PneumoniaInfections and infestations10/3468/349
Myocardial infarctionCardiac disorders4/3469/349
Gastrointestinal haemorrhageGastrointestinal disorders5/3469/349
Cardiac arrestCardiac disorders2/3468/349
Atrial fibrillationCardiac disorders7/3465/349
SepsisInfections and infestations2/3467/349
HyperkalaemiaMetabolism and nutrition disorders2/3467/349
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders5/3467/349
Respiratory failureRespiratory, thoracic and mediastinal disorders1/3467/349
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSomatropinPlacebo
NauseaGastrointestinal disorders29/34636/349
DiarrhoeaGastrointestinal disorders23/34636/349
VomitingGastrointestinal disorders17/34629/349
Pain in extremityMusculoskeletal and connective tissue disorders25/34619/349
CoughRespiratory, thoracic and mediastinal disorders14/34625/349
HypotensionVascular disorders24/34623/349
HeadacheNervous system disorders23/34622/349
DyspnoeaRespiratory, thoracic and mediastinal disorders22/34622/349
ArthralgiaMusculoskeletal and connective tissue disorders21/34622/349
AstheniaGeneral disorders9/34619/349

Baseline characteristics

Age, Continuous
Age, Continuous(years)SomatropinPlaceboTotal
Mean62.2 ± 13.561.0 ± 14.261.6 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)SomatropinPlaceboTotal
Female175139314
Male171210381
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SomatropinPlaceboTotal
Hispanic or Latino5566121
Not Hispanic or Latino286279565
Unknown or Not Reported549
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SomatropinPlaceboTotal
American Indian or Alaska Native213
Asian8412
Native Hawaiian or Other Pacific Islander011
Black or African American114113227
White205213418
More than one race141731
Unknown or Not Reported303
Diabetes
Diabetes(participants)SomatropinPlaceboTotal
Type 1 diabetes mellitus121628
Type 2 diabetes mellitus161150311
Not Diabetic173183356
BMI
BMI(kg/m2)SomatropinPlaceboTotal
Mean28.9 ± 8.628.4 ± 8.028.7 ± 8.3
Duration of Diabetes
Duration of Diabetes(years)SomatropinPlaceboTotal
Median17.5 (1.6 to 63.6)20.3 (1.2 to 58.5)18.4 (1.2 to 63.6)
Duration of Dialysis
Duration of Dialysis(years)SomatropinPlaceboTotal
Median2.9 (0.2 to 27.1)2.9 (0.3 to 34.6)2.9 (0.2 to 34.6)

2 further baseline measures are reported on the registry.

09

Study locations

381 sites
  • Novo Nordisk Investigational Site
    Alexander City, Alabama 35010, United States
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35211, United States
  • Novo Nordisk Investigational Site
    Madison, Alabama 35758, United States
  • Novo Nordisk Investigational Site
    Mobile, Alabama 36608, United States
  • Novo Nordisk Investigational Site
    Mobile, Alabama 36617, United States
  • Novo Nordisk Investigational Site
    Montgomery, Alabama 36106, United States
  • Novo Nordisk Investigational Site
    Glendale, Arizona 85306, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85012, United States
  • Novo Nordisk Investigational Site
    Tempe, Arizona 85284, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85719, United States
  • Novo Nordisk Investigational Site
    Tuscon, Arizona 85723, United States
  • Novo Nordisk Investigational Site
    Eldorado, Arkansas 71730, United States
  • Novo Nordisk Investigational Site
    Fort Smith, Arkansas 72901, United States
  • Novo Nordisk Investigational Site
    Hot Springs, Arkansas 71901, United States
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72204, United States
  • Novo Nordisk Investigational Site
    McGehee, Arkansas 71654, United States
  • Novo Nordisk Investigational Site
    Paragould, Arkansas 72450, United States
  • Novo Nordisk Investigational Site
    Pine Bluff, Arkansas 71603, United States
  • Novo Nordisk Investigational Site
    Beverly Hills, California 90211, United States
  • Novo Nordisk Investigational Site
    Chula Vista, California 91910, United States
  • Novo Nordisk Investigational Site
    Covina, California 91723, United States
  • Novo Nordisk Investigational Site
    Escondido, California 92025, United States
  • Novo Nordisk Investigational Site
    Glendale, California 91205, United States
  • Novo Nordisk Investigational Site
    La Mesa, California 91942, United States
  • Novo Nordisk Investigational Site
    Lakewood, California 90712, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90822, United States
  • Novo Nordisk Investigational Site
    Los Alamitos, California 90720, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90017, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90033, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90095, United States
  • Novo Nordisk Investigational Site
    Lynwood, California 90262, United States
  • Novo Nordisk Investigational Site
    Merced, California 95340, United States
  • Novo Nordisk Investigational Site
    Mission Hills, California 91345, United States
  • Novo Nordisk Investigational Site
    Monterey Park, California 91745, United States
  • Novo Nordisk Investigational Site
    Mountain View, California 94041, United States
  • Novo Nordisk Investigational Site
    Pasadena, California 91106, United States
  • Novo Nordisk Investigational Site
    Porterville, California 93257, United States
  • Novo Nordisk Investigational Site
    Riverside, California 92505, United States
  • Novo Nordisk Investigational Site
    Sacramento, California 95825, United States
  • Novo Nordisk Investigational Site
    Torrance, California 90502, United States
  • Novo Nordisk Investigational Site
    Vacaville, California 95687, United States
  • Novo Nordisk Investigational Site
    Visalia, California 93277, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Whittier, California 90602, United States
  • Novo Nordisk Investigational Site
    Whittier, California 90603-2313, United States
  • Novo Nordisk Investigational Site
    Yuba City, California 95991, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80909, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80220, United States
  • Novo Nordisk Investigational Site
    Lakewood, Colorado 80214, United States
  • Novo Nordisk Investigational Site
    Middlebury, Connecticut 06762, United States
  • Novo Nordisk Investigational Site
    Stamford, Connecticut 06902, United States
  • Novo Nordisk Investigational Site
    Washington, District of Columbia 20002, United States
  • Novo Nordisk Investigational Site
    Atlantis, Florida 33462, United States
  • Novo Nordisk Investigational Site
    Brandon, Florida 33511, United States
  • Novo Nordisk Investigational Site
    Coral Springs, Florida 33071, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32224, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33173, United States
  • Novo Nordisk Investigational Site
    Naples, Florida 34119, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32804, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32806, United States
  • Novo Nordisk Investigational Site
    Panama City, Florida 32401, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33603, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33614, United States
  • Novo Nordisk Investigational Site
    Weston, Florida 33331, United States
  • Novo Nordisk Investigational Site
    Zephyrhills, Florida 33542, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30329, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30331, United States
  • Novo Nordisk Investigational Site
    Augusta, Georgia 30901, United States
  • Novo Nordisk Investigational Site
    Augusta, Georgia 30912-3260, United States
  • Novo Nordisk Investigational Site
    Macon, Georgia 31217, United States
  • Novo Nordisk Investigational Site
    Marietta, Georgia 30066, United States
  • Novo Nordisk Investigational Site
    Boise, Idaho 83706, United States
  • Novo Nordisk Investigational Site
    Meridian, Idaho 83642, United States
  • Novo Nordisk Investigational Site
    Crestwood, Illinois 60445, United States
  • Novo Nordisk Investigational Site
    Evergreen Park, Illinois 60805, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    Maywood, Illinois 60153, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46202, United States
  • Novo Nordisk Investigational Site
    Michigan City, Indiana 46360, United States
  • Novo Nordisk Investigational Site
    Des Moines, Iowa 50309, United States
  • Novo Nordisk Investigational Site
    Kansas City, Kansas 66160, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Wichita, Kansas 67214, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40513, United States
  • Novo Nordisk Investigational Site
    Madisonville, Kentucky 42431, United States
  • Novo Nordisk Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • Novo Nordisk Investigational Site
    Lafayatte, Louisiana 70506, United States
  • Novo Nordisk Investigational Site
    New Iberia, Louisiana 70563, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70112, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70115, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70121, United States
  • Novo Nordisk Investigational Site
    Shreveport, Louisiana 71101, United States
  • Novo Nordisk Investigational Site
    Bethesda, Maryland 20814, United States
  • Novo Nordisk Investigational Site
    Easton, Maryland 21601, United States
  • Novo Nordisk Investigational Site
    Hagerstown, Maryland 21740, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Silver Spring, Maryland 20906, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02215, United States

Showing the first 100 of 381 sites across 21 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, Lange M, Mitch WE, Wanner C, Wiedemann J, Ikizler TA. OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol. 2008 Nov;3(6):1741-51. doi: 10.2215/CJN.02760608. PubMed 18945992 ↗
  • Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr Opin Nephrol Hypertens. 2008 Nov;17(6):560-5. doi: 10.1097/MNH.0b013e32830f45b6. PubMed 18941347 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2007
First posted
Jul 19, 2007
Start
Jul 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jul 13, 2010
Last update
Mar 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00503698
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 19, 2007
Start date
Jul 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jul 13, 2010
Last update
Mar 7, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion